The latest news:

• ONC201 Trial for Histone Mutant Glioma Begins at NYU         This mutation is a bad prognostic sign, but they have a 15 year survivor on this medication.  
  



• Making medicine, not money: How one U of T researcher's startup is rethinking Big Pharma's business model         I love this model. Combine it with our proposal to speed up access to experimental drugs and we may have a cure much sooner than we thought!
  



• Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models         This is a new way to target brain tumors.  We are proud to say the Musella Foundation was one of the sponsors of the research.
  



• Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.         Unfortunately, the combination did not do any better than Avastin alone
  



• Liquid Biopsy Spots Aggressive Pediatric Brainstem Cancer Earlier         This blood (and spinal fluid) test can help diagnose and  monitor the response to treatment for these devastating tumors.  There are drugs under development which target the marker mentioned, so this blood test might be able to be used to determine which patients get these new drugs, without the need for biopsies. Amazing stuff.  And we are proud to say we are one of the sponsors.  Your donations at work!
  



• Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55         Impressive results. 20% complete response rate form a single injection of this drug, and no serious side effects.  This is the type of treatment that should be approved immediately.
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants